A vs. VTRS: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at A and VTRS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | A | VTRS |
|---|---|---|
| Company Name | Agilent Technologies, Inc. | Viatris Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Life Sciences Tools & Services | Pharmaceuticals |
| Market Capitalization | 41.68 billion USD | 12.54 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | November 18, 1999 | March 17, 1980 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of A and VTRS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | A | VTRS |
|---|---|---|
| 5-Day Price Return | 0.31% | 5.41% |
| 13-Week Price Return | 23.17% | 1.04% |
| 26-Week Price Return | 27.20% | 21.96% |
| 52-Week Price Return | 9.34% | -17.54% |
| Month-to-Date Return | 0.31% | 3.47% |
| Year-to-Date Return | 9.29% | -13.90% |
| 10-Day Avg. Volume | 1.58M | 11.32M |
| 3-Month Avg. Volume | 1.67M | 9.24M |
| 3-Month Volatility | 29.31% | 30.81% |
| Beta | 1.28 | 0.81 |
Profitability
Return on Equity (TTM)
A
19.97%
Life Sciences Tools & Services Industry
- Max
- 23.81%
- Q3
- 11.79%
- Median
- 7.51%
- Q1
- 3.14%
- Min
- -6.95%
In the upper quartile for the Life Sciences Tools & Services industry, A’s Return on Equity of 19.97% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
VTRS
-22.69%
Pharmaceuticals Industry
- Max
- 38.95%
- Q3
- 20.34%
- Median
- 11.59%
- Q1
- 3.32%
- Min
- -10.91%
VTRS has a negative Return on Equity of -22.69%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
A
17.97%
Life Sciences Tools & Services Industry
- Max
- 33.77%
- Q3
- 17.97%
- Median
- 8.97%
- Q1
- 3.80%
- Min
- -11.89%
A’s Net Profit Margin of 17.97% is aligned with the median group of its peers in the Life Sciences Tools & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
VTRS
-26.13%
Pharmaceuticals Industry
- Max
- 39.07%
- Q3
- 19.28%
- Median
- 13.48%
- Q1
- 5.73%
- Min
- -8.86%
VTRS has a negative Net Profit Margin of -26.13%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
A
21.26%
Life Sciences Tools & Services Industry
- Max
- 31.55%
- Q3
- 21.26%
- Median
- 14.06%
- Q1
- 8.54%
- Min
- 0.11%
A’s Operating Profit Margin of 21.26% is around the midpoint for the Life Sciences Tools & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
VTRS
-21.26%
Pharmaceuticals Industry
- Max
- 45.58%
- Q3
- 24.35%
- Median
- 18.05%
- Q1
- 7.58%
- Min
- -11.88%
VTRS has a negative Operating Profit Margin of -21.26%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | A | VTRS |
|---|---|---|
| Return on Equity (TTM) | 19.97% | -22.69% |
| Return on Assets (TTM) | 10.14% | -9.45% |
| Net Profit Margin (TTM) | 17.97% | -26.13% |
| Operating Profit Margin (TTM) | 21.26% | -21.26% |
| Gross Profit Margin (TTM) | 52.92% | 39.36% |
Financial Strength
Current Ratio (MRQ)
A
2.25
Life Sciences Tools & Services Industry
- Max
- 4.76
- Q3
- 2.87
- Median
- 1.75
- Q1
- 1.37
- Min
- 0.57
A’s Current Ratio of 2.25 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.
VTRS
1.35
Pharmaceuticals Industry
- Max
- 5.45
- Q3
- 2.99
- Median
- 1.98
- Q1
- 1.29
- Min
- 0.78
VTRS’s Current Ratio of 1.35 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
A
0.54
Life Sciences Tools & Services Industry
- Max
- 0.95
- Q3
- 0.70
- Median
- 0.45
- Q1
- 0.18
- Min
- 0.00
A’s Debt-to-Equity Ratio of 0.54 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
VTRS
0.95
Pharmaceuticals Industry
- Max
- 1.79
- Q3
- 0.78
- Median
- 0.31
- Q1
- 0.08
- Min
- 0.00
VTRS’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 0.95. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
A
254.50
Life Sciences Tools & Services Industry
- Max
- 45.00
- Q3
- 27.84
- Median
- 7.16
- Q1
- 2.12
- Min
- -14.08
With an Interest Coverage Ratio of 254.50, A demonstrates a superior capacity to service its debt, placing it well above the typical range for the Life Sciences Tools & Services industry. This stems from either robust earnings or a conservative debt load.
VTRS
-0.13
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 10.15
- Q1
- 2.37
- Min
- -42.71
VTRS has a negative Interest Coverage Ratio of -0.13. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | A | VTRS |
|---|---|---|
| Current Ratio (MRQ) | 2.25 | 1.35 |
| Quick Ratio (MRQ) | 1.71 | 0.68 |
| Debt-to-Equity Ratio (MRQ) | 0.54 | 0.95 |
| Interest Coverage Ratio (TTM) | 254.50 | -0.13 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
A
0.67%
Life Sciences Tools & Services Industry
- Max
- 1.02%
- Q3
- 0.67%
- Median
- 0.32%
- Q1
- 0.00%
- Min
- 0.00%
A’s Dividend Yield of 0.67% is consistent with its peers in the Life Sciences Tools & Services industry, providing a dividend return that is standard for its sector.
VTRS
4.84%
Pharmaceuticals Industry
- Max
- 6.72%
- Q3
- 3.48%
- Median
- 1.90%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 4.84%, VTRS offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio (TTM)
A
22.95%
Life Sciences Tools & Services Industry
- Max
- 97.67%
- Q3
- 61.34%
- Median
- 18.53%
- Q1
- 0.00%
- Min
- 0.00%
A’s Dividend Payout Ratio of 22.95% is within the typical range for the Life Sciences Tools & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
VTRS
137.04%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 85.87%
- Median
- 49.36%
- Q1
- 1.12%
- Min
- 0.00%
VTRS’s Dividend Payout Ratio of 137.04% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
Dividend at a Glance
| Symbol | A | VTRS |
|---|---|---|
| Dividend Yield (TTM) | 0.67% | 4.84% |
| Dividend Payout Ratio (TTM) | 22.95% | 137.04% |
Valuation
Price-to-Earnings Ratio (TTM)
A
34.12
Life Sciences Tools & Services Industry
- Max
- 78.22
- Q3
- 57.42
- Median
- 34.18
- Q1
- 28.39
- Min
- 1.55
A’s P/E Ratio of 34.12 is within the middle range for the Life Sciences Tools & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
VTRS
--
Pharmaceuticals Industry
- Max
- 52.64
- Q3
- 29.89
- Median
- 20.77
- Q1
- 13.37
- Min
- 5.71
P/E Ratio data for VTRS is currently unavailable.
Price-to-Sales Ratio (TTM)
A
6.13
Life Sciences Tools & Services Industry
- Max
- 10.69
- Q3
- 6.37
- Median
- 4.95
- Q1
- 3.27
- Min
- 1.04
A’s P/S Ratio of 6.13 aligns with the market consensus for the Life Sciences Tools & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
VTRS
0.83
Pharmaceuticals Industry
- Max
- 8.74
- Q3
- 4.66
- Median
- 2.37
- Q1
- 1.67
- Min
- 0.11
In the lower quartile for the Pharmaceuticals industry, VTRS’s P/S Ratio of 0.83 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
A
5.12
Life Sciences Tools & Services Industry
- Max
- 8.12
- Q3
- 5.04
- Median
- 3.94
- Q1
- 2.12
- Min
- 1.13
A’s P/B Ratio of 5.12 is in the upper tier for the Life Sciences Tools & Services industry. This indicates that investors are paying a premium relative to the company’s net assets, a valuation that hinges on its ability to generate superior profits.
VTRS
0.76
Pharmaceuticals Industry
- Max
- 9.86
- Q3
- 5.28
- Median
- 2.48
- Q1
- 1.57
- Min
- 0.59
VTRS’s P/B Ratio of 0.76 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | A | VTRS |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 34.12 | -- |
| Price-to-Sales Ratio (TTM) | 6.13 | 0.83 |
| Price-to-Book Ratio (MRQ) | 5.12 | 0.76 |
| Price-to-Free Cash Flow Ratio (TTM) | 38.26 | 7.26 |